US 7,531,173 B2
	Ophthalmic composition of a VEGF antagonist
Stanley J. Wiegand, Croton-on-Hudson, N.Y. (US); and Jingtai Cao, Chappaqua, N.Y. (US)
Assigned to Regeneron Pharmaceuticals, Inc., Tarrytown, N.Y. (US)
Filed on Nov. 30, 2007, as Appl. No. 11/998,746.
Application 11/998746 is a division of application No. 11/346009, filed on Feb. 02, 2006, granted, now 7,303,748.
Claims priority of provisional application 60/649232, filed on Feb. 02, 2005.
Prior Publication US 2008/0085276 A1, Apr. 10, 2008
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/18 (2006.01); C07K 14/71 (2006.01); C12N 15/62 (2006.01)

U.S. Cl. 424—134.1  [424/192.1; 514/2; 514/12; 530/350; 536/23.4]

2 Claims

1. An ophthalmic composition comprising a vascular endothelial growth factor (VEGF) antagonist in a pharmaceutically acceptable carrier, wherein the VEGF antagonist is VEGFR1R2-FcΔC1(a) polypeptide.